{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:23:49Z","timestamp":1787678629672,"version":"build-2784847793"},"reference-count":73,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2025,1,31]]},"DOI":"10.1536\/ihj.24-615","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:14:13Z","timestamp":1738275253000},"page":"3-12","source":"Crossref","is-referenced-by-count":12,"title":["Exploring Novel Therapeutics for Pulmonary Arterial Hypertension"],"prefix":"10.1536","volume":"66","author":[{"given":"Takayuki","family":"Fujiwara","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo Hospital"},{"name":"Department of Computational Diagnostic Radiology and Preventive Medicine, Graduate School of Medicine, The University of Tokyo"},{"name":"Center for Molecular Medicine, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Minatsuki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo Hospital"},{"name":"Advanced Medical Center for Heart Failure, The University of Tokyo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Rich JD, Rich S. Clinical diagnosis of pulmonary hypertension. Circulation 2014; 130: 1820-30.","DOI":"10.1161\/CIRCULATIONAHA.114.006971"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Simonneau G, Montani D, Celermajer DS, <i>et al<\/i>. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913.","DOI":"10.1183\/13993003.01913-2018"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Tuder RM, Stacher E, Robinson J, <i>et al<\/i>. Pathology of pulmonary hypertension. Clinics in Chest Medicine 2013; 34: 639-50.","DOI":"10.1016\/j.ccm.2013.08.009"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Jonigk D, Golpon H, Bockmeyer CL, <i>et al<\/i>. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol 2011; 179: 167-79.","DOI":"10.1016\/j.ajpath.2011.03.040"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Galie N, Humbert M, Vachiery JL, <i>et al<\/i>. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67-119.","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Machado RD, Southgate L, Eichstaedt CA, <i>et al<\/i>. Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Hum Mutat 2015; 36: 1113-27.","DOI":"10.1002\/humu.22904"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Atkinson C, Stewart S, Upton PD, <i>et al<\/i>. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002; 105: 1672-8.","DOI":"10.1161\/01.CIR.0000012754.72951.3D"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Austin ED, Loyd JE. The genetics of pulmonary arterial hypertension. Circ Res 2014; 115: 189-202.","DOI":"10.1161\/CIRCRESAHA.115.303404"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Long L, Ormiston ML, Yang X, <i>et al<\/i>. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med 2015; 21: 777-85.","DOI":"10.1038\/nm.3877"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yang J, Li X, Al-Lamki RS, <i>et al<\/i>. Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 2013; 33: 34-42.","DOI":"10.1161\/ATVBAHA.112.300121"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Spiekerkoetter E, Tian X, Cai J, <i>et al<\/i>. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. Journal of Clinical Investigation 2013; 123: 3600-13.","DOI":"10.1172\/JCI65592"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Spiekerkoetter E, Sung YK, Sudheendra D, <i>et al<\/i>. Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. Eur Respir J 2017; 50: 1602449.","DOI":"10.1183\/13993003.02449-2016"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yung LM, Yang P, Joshi S, <i>et al<\/i>. ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med 2020; 12: eaaz5660.","DOI":"10.1126\/scitranslmed.aaz5660"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ogo T, Chowdhury HM, Yang J, <i>et al<\/i>. Inhibition of overactive transforming growth factor-beta signaling by prostacyclin analogs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2013; 48: 733-41.","DOI":"10.1165\/rcmb.2012-0049OC"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Humbert M, McLaughlin V, Gibbs JSR, <i>et al<\/i>. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engle J Med 2021; 384: 1204-15.","DOI":"10.1056\/NEJMoa2024277"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hoeper MM, Badesch DB, Ghofrani HA, <i>et al<\/i>. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engle J Med 2023; 388: 1478-90.","DOI":"10.1056\/NEJMoa2213558"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Harmon GS, Lam MT, Glass CK. PPARs and lipid ligands in inflammation and metabolism. Chem Rev 2011; 111: 6321-40.","DOI":"10.1021\/cr2001355"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ameshima S, Golpon H, Cool CD, <i>et al<\/i>. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 2003; 92: 1162-9.","DOI":"10.1161\/01.RES.0000073585.50092.14"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nisbet RE, Bland JM, Kleinhenz DJ, <i>et al<\/i>. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol 2010; 42: 482-90.","DOI":"10.1165\/rcmb.2008-0132OC"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Legchenko E, Chouvarine P, Borchert P, <i>et al<\/i>. PPARgamma agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med 2018; 10: eaao0303.","DOI":"10.1126\/scitranslmed.aao0303"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Calvier L, Chouvarine P, Legchenko E, <i>et al<\/i>. PPARgamma Links BMP2 and TGFbeta1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism. Cell Metab 2017; 25: 1118-34 e7.","DOI":"10.1016\/j.cmet.2017.03.011"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hansmann G, de Jesus Perez VA, Alastalo TP, <i>et al<\/i>. An antiproliferative BMP-2\/PPARgamma\/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008; 118: 1846-57.","DOI":"10.1172\/JCI32503"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Nesto RW, Bell D, Bonow RO, <i>et al<\/i>. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003; 108: 2941-8.","DOI":"10.1161\/01.CIR.0000103683.99399.7E"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Omura J, Satoh K, Kikuchi N, <i>et al<\/i>. Protective Roles of Endothelial AMP-Activated Protein Kinase Against Hypoxia-Induced Pulmonary Hypertension in Mice. Circ Res 2016; 119: 197-209.","DOI":"10.1161\/CIRCRESAHA.115.308178"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Brittain EL, Niswender K, Agrawal V, <i>et al<\/i>. Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension. J Am Heart Assoc 2020; 9: e018349.","DOI":"10.1161\/JAHA.120.018349"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Uthman L, Homayr A, Juni RP, <i>et al<\/i>. Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor alpha-Stimulated Human Coronary Arterial Endothelial Cells. Cell Physiol Biochem 2019; 53: 865-86.","DOI":"10.33594\/000000178"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tang Y, Tan S, Li M, <i>et al<\/i>. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension. BMC Pulm Med 2022; 22: 142.","DOI":"10.1186\/s12890-022-01939-7"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Chowdhury B, Luu AZ, Luu VZ, <i>et al<\/i>. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem Biophys Res Commun 2020; 524: 50-6.","DOI":"10.1016\/j.bbrc.2020.01.015"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Li XC, Zhu XY, Wang YY, <i>et al<\/i>. Canagliflozin alleviates pulmonary hypertension by activating PPARgamma and inhibiting its S225 phosphorylation. Acta Pharmacol Sin 2024; 45: 1861-78.","DOI":"10.1038\/s41401-024-01286-9"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Helmstadter J, Frenis K, Filippou K, <i>et al<\/i>. Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension. Arterioscler Thromb Vasc Biol 2020; 40: 145-58.","DOI":"10.1161\/atv.0000615456.97862.30"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Lee MY, Tsai KB, Hsu JH, <i>et al<\/i>. Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS\/sGC\/PKG pathways. Sci Rep 2016; 6: 31788.","DOI":"10.1038\/srep31788"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Wu YC, Wang WT, Lee SS, <i>et al<\/i>. Glucagon-Like Peptide-1 Receptor Agonist Attenuates Autophagy to Ameliorate Pulmonary Arterial Hypertension through Drp1\/NOX- and Atg-5\/Atg-7\/Beclin-1\/LC3beta Pathways. Int J Mol Sci 2019; 20: 3435.","DOI":"10.3390\/ijms20143435"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, <i>et al<\/i>. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.","DOI":"10.1016\/j.cmet.2007.10.002"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Bertero T, Oldham WM, Cottrill KA, <i>et al<\/i>. Vascular stiffness mechanoactivates YAP\/TAZ-dependent glutaminolysis to drive pulmonary hypertension. J Clin Invest 2016; 126: 3313-35.","DOI":"10.1172\/JCI86387"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Acharya AP, Tang Y, Bertero T, <i>et al<\/i>. Simultaneous Pharmacologic Inhibition of Yes-Associated Protein 1 and Glutaminase 1 via Inhaled Poly (Lactic-co-Glycolic) Acid-Encapsulated Microparticles Improves Pulmonary Hypertension. J Am Heart Assoc 2021; 10: e019091.","DOI":"10.1161\/JAHA.120.019091"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Larkin EK, Newman JH, Austin ED, <i>et al<\/i>. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 892-6.","DOI":"10.1164\/rccm.201205-0886OC"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 2008; 44: 14-30.","DOI":"10.1016\/j.yjmcc.2007.09.006"},{"key":"38","unstructured":"38. Tuder RM, Groves B, Badesch DB, <i>et al<\/i>. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-85."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Rabinovitch M, Guignabert C, Humbert M, <i>et al<\/i>. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014; 115: 165-75.","DOI":"10.1161\/CIRCRESAHA.113.301141"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Soon E, Holmes AM, Treacy CM, <i>et al<\/i>. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010; 122: 920-7.","DOI":"10.1161\/CIRCULATIONAHA.109.933762"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Elisa T, Antonio P, Giuseppe P, <i>et al<\/i>. Endothelin Receptors Expressed by Immune Cells Are Involved in Modulation of Inflammation and in Fibrosis: Relevance to the Pathogenesis of Systemic Sclerosis. J Immunol Res 2015; 2015: 147616.","DOI":"10.1155\/2015\/147616"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Tsai BM, Turrentine MW, Sheridan BC, <i>et al<\/i>. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg 2006; 81: 272-8.","DOI":"10.1016\/j.athoracsur.2005.06.040"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Hashimoto-Kataoka T, Hosen N, Sonobe T, <i>et al<\/i>. Interleukin-6\/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A 2015; 112: E2677-86.","DOI":"10.1073\/pnas.1424774112"},{"key":"44","unstructured":"44. Bhargava A, Kumar A, Yuan N, <i>et al<\/i>. Monocrotaline induces interleukin-6 mRNA expression in rat lungs. Heart Dis 1999; 1: 126-32."},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Steiner MK, Syrkina OL, Kolliputi N, <i>et al<\/i>. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009; 104: 236-44.","DOI":"10.1161\/CIRCRESAHA.108.182014"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Savale L, Tu L, Rideau D, <i>et al<\/i>. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 2009; 10: 6.","DOI":"10.1186\/1465-9921-10-6"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010; 49: 15-24.","DOI":"10.1093\/rheumatology\/kep329"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. De Benedetti F, Brunner HI, Ruperto N, <i>et al<\/i>. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engle J Med 2012; 367: 2385-95.","DOI":"10.1056\/NEJMoa1112802"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Toshner M, Church C, Harbaum L, <i>et al<\/i>. Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. Eur Respir J 2022; 59: 2002463.","DOI":"10.1183\/13993003.02463-2020"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Li XQ, Wang HM, Yang CG, <i>et al<\/i>. Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats. Acta Pharmacol Sin 2011; 32: 217-22.","DOI":"10.1038\/aps.2010.187"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Fujita M, Shannon JM, Irvin CG, <i>et al<\/i>. Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001; 280: L39-49.","DOI":"10.1152\/ajplung.2001.280.1.L39"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Hurst LA, Dunmore BJ, Long L, <i>et al<\/i>. TNFalpha drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling. Nat Commun 2017; 8: 14079.","DOI":"10.1038\/ncomms14079"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Meloche J, Pflieger A, Vaillancourt M, <i>et al<\/i>. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014; 129: 786-97.","DOI":"10.1161\/CIRCULATIONAHA.113.006167"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Chen JH, Hales CN, Ozanne SE. DNA damage, cellular senescence and organismal ageing: causal or correlative? Nucleic Acids Research 2007; 35: 7417-28.","DOI":"10.1093\/nar\/gkm681"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Narasimhan A, Flores RR, Robbins PD, <i>et al<\/i>. Role of Cellular Senescence in Type II Diabetes. Endocrinology 2021; 162: bqab136.","DOI":"10.1210\/endocr\/bqab136"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Honda S, Ikeda K, Urata R, <i>et al<\/i>. Cellular senescence promotes endothelial activation through epigenetic alteration, and consequently accelerates atherosclerosis. Sci Rep 2021; 11: 14608.","DOI":"10.1038\/s41598-021-94097-5"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Schafer MJ, White TA, Iijima K, <i>et al<\/i>. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun 2017; 8: 14532.","DOI":"10.1038\/ncomms14532"},{"key":"58","doi-asserted-by":"publisher","unstructured":"58. Born E, Lipskaia L, Breau M, <i>et al<\/i>. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation 2023; 147: 650-66.","DOI":"10.1161\/CIRCULATIONAHA.122.058794"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Voelkel NF, Gomez-Arroyo J. The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox. Am J Respir Cell Mol Biol 2014; 51: 474-84.","DOI":"10.1165\/rcmb.2014-0045TR"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Pankey EA, Thammasiboon S, Lasker GF, <i>et al<\/i>. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat. Am J Physiol Heart Circ Physiol 2013; 305: H1288-96.","DOI":"10.1152\/ajpheart.00329.2013"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Ciuclan L, Hussey MJ, Burton V, <i>et al<\/i>. Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression. Am J Respir Crit Care Med 2013; 187: 78-89.","DOI":"10.1164\/rccm.201206-1028OC"},{"key":"62","doi-asserted-by":"publisher","unstructured":"62. Hoeper MM, Barst RJ, Bourge RC, <i>et al<\/i>. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127: 1128-38.","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Frantz RP, McLaughlin VV, Sahay S, <i>et al<\/i>. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med 2024; 12: 523-34.","DOI":"10.1016\/S2213-2600(24)00072-9"},{"key":"64","doi-asserted-by":"publisher","unstructured":"64. Montani D, Bergot E, Gunther S, <i>et al<\/i>. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-37.","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Guignabert C, Phan C, Seferian A, <i>et al<\/i>. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 2016; 126: 3207-18.","DOI":"10.1172\/JCI86249"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Dai Z, Li M, Wharton J, <i>et al<\/i>. Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2alpha. Circulation 2016; 133: 2447-58.","DOI":"10.1161\/CIRCULATIONAHA.116.021494"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Partovian C, Adnot S, Raffestin B, <i>et al<\/i>. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am J Respir Cell Mol Biol 2000; 23: 762-71.","DOI":"10.1165\/ajrcmb.23.6.4106"},{"key":"68","doi-asserted-by":"publisher","unstructured":"68. Abe K, Toba M, Alzoubi A, <i>et al<\/i>. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010; 121: 2747-54.","DOI":"10.1161\/CIRCULATIONAHA.109.927681"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Sitapara R, Sugarragchaa C, Zisman LS. SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling. Pulm Circ 2021; 11: 20458940211021528.","DOI":"10.1177\/20458940211021528"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Masaki T, Okazawa M, Asano R, <i>et al<\/i>. Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A 2021; 118: e2023899118.","DOI":"10.1073\/pnas.2023899118"},{"key":"71","doi-asserted-by":"crossref","first-page":"e162632","DOI":"10.1172\/jci.insight.162632","volume":"8","year":"2023","unstructured":"71. Fujiwara T, Takeda N, Hara H, <i>et al<\/i>. PGC-1alpha-mediated angiogenesis prevents pulmonary hypertension in mice. JCI Insight 2023; 8: e162632.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Akiyama T, Sadahiro T, Yamada Y, <i>et al<\/i>. Flk1 Deficiency and Hypoxia Synergistically Promote Endothelial Dysfunction, Vascular Remodeling, and Pulmonary Hypertension. Arterioscler Thromb Vasc Biol 2023; 43: 1668-83.","DOI":"10.1161\/ATVBAHA.123.319266"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Fujiwara T, Takeda N, Hara H, <i>et al<\/i>. Three-Dimensional Visualization of Hypoxia-Induced Pulmonary Vascular Remodeling in Mice. Circulation 2021; 144: 1452-5.","DOI":"10.1161\/CIRCULATIONAHA.121.056219"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/66\/1\/66_24-615\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T04:21:23Z","timestamp":1738383683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/66\/1\/66_24-615\/_article"}},"subtitle":["From the Bench to the Bedside"],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.24-615","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"article-number":"24-615"}}